NCT06295744 Outcomes and Cosmesis With Whole Breast Irradiation and Boost
| NCT ID | NCT06295744 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Wisconsin, Madison |
| Condition | Early-stage Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-04-17 |
| Primary Completion | 2029-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-04-17 with a primary completion date of 2029-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will be on study for up to 60 months.
Eligibility Criteria
Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Histologically confirmed early stage (stage T1-T2) invasive carcinoma of the breast or DCIS * Breast conserving surgery with negative margins and negative nodes (surgical axillary staging not mandatory), stage N0 or Nx * Treatment plan should include breast conserving surgery and adjuvant whole breast irradiation (WBI) therapy delivered with 3D-CRT or IMRT techniques * Treatment plan includes breast tumor bed boost * Willingness to comply with all study procedures and be available for the duration of the study Exclusion Criteria: * Mastectomy of ipsilateral breast * Lack of histologic diagnosis * Histologic involvement of the axillary or regional nodes or metastatic disease * Accelerated partial breast irradiation treatment plan * Previous history of non-breast malignancy diagnosed in the past 5 years except for basal or squamous cell cancer of the skin * Previous history of chest radiation therapy * Previous history of ipsilateral breast cancer * Concurrent cytotoxic chemotherapy * Active connective tissue disease including scleroderma * Inability or unwillingness to return for required follow up visit
Contact & Investigator
Jessica Schuster, MD
PRINCIPAL INVESTIGATOR
UW Carbone Cancer Center
Frequently Asked Questions
Who can join the NCT06295744 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Early-stage Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06295744 currently recruiting?
Yes, NCT06295744 is actively recruiting participants. Contact the research team at clinicaltrials@cancer.wisc.edu for enrollment information.
Where is the NCT06295744 trial being conducted?
This trial is being conducted at Madison, United States.
Who is sponsoring the NCT06295744 clinical trial?
NCT06295744 is sponsored by University of Wisconsin, Madison. The principal investigator is Jessica Schuster, MD at UW Carbone Cancer Center. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.